-
Je něco špatně v tomto záznamu ?
The role of a center for tobacco-dependent in cardiovascular prevention. A retrospective study
K. Zvolska, E. Kralikova, A. Kmetova, L. Stepankova, M. Blaha, M. Sticha, Z. Bortlicek, R. Ceska,
Jazyk angličtina Země Švédsko
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NT12170
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
ROAD: Directory of Open Access Scholarly Resources
od 2012
PubMed
23183520
Knihovny.cz E-zdroje
- MeSH
- chování snižující riziko MeSH
- dospělí MeSH
- kardiovaskulární nemoci epidemiologie prevence a kontrola MeSH
- lidé středního věku MeSH
- lidé MeSH
- logistické modely MeSH
- multivariační analýza MeSH
- následné studie MeSH
- odvykání kouření statistika a číselné údaje MeSH
- poruchy vyvolané užíváním tabáku epidemiologie terapie MeSH
- prevalence MeSH
- průřezové studie MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
OBJECTIVES: Smoking cessation is an essential part of cardiovascular disease (CVD) prevention. At the Center for Tobacco-Dependent (CTD), clients are screened to identify and reduce cardiovascular (CV) risk factors. In our study we have focused on the role of the CTD in reducing global CV risk. METHODS: 1,334 CTD patients aged 25-64 years (52.2% men, mean age 44±12 years, Fagerström Test for Cigarette Dependence 6±2) were included in a retrospective cross-sectional survey. Medical history, blood samples and physical examination were analysed. Blood pressure, weight and exhaled CO were measured at each visit (12-months-follow-up). Patients' CV risk was scored. CO-verified abstinence according to CV risk and prevalence of detected CV risk factors were examined. RESULTS: Among patients who had attended at least their first visit and a visit after one year, 37.9% (506/1,334) had stopped smoking. Among patients with a SCORE of <5%, the success rate was 44.3% (254/574) and 41.2% for patients at high CV risk (105/255, p=0.41). There was a trend towards a lower success rate among patients with CVD, but this difference was not significant. The smoking cessation rate among low and high CV risk patients at the baseline visit was identical (46.2%, resp. 47.3%, p=0.81). 3.1% (42/1,334) of patients were referred to a specialist for hypertension. 62.5% (223/357), without a prior history, were found to have dyslipidemia. CONCLUSIONS: High CV risk patients have the same chance to stop smoking as low risk patients.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024101
- 003
- CZ-PrNML
- 005
- 20190708143747.0
- 007
- ta
- 008
- 130703s2012 sw f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)23183520
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sw
- 100 1_
- $a Zvolská, Kamila, $u Department of Endocrinology and Metabolism, Charles University and General University Hospital, Prague, Czech Republic. kzvolska@centrum.cz $d 1980- $7 xx0214179
- 245 14
- $a The role of a center for tobacco-dependent in cardiovascular prevention. A retrospective study / $c K. Zvolska, E. Kralikova, A. Kmetova, L. Stepankova, M. Blaha, M. Sticha, Z. Bortlicek, R. Ceska,
- 520 9_
- $a OBJECTIVES: Smoking cessation is an essential part of cardiovascular disease (CVD) prevention. At the Center for Tobacco-Dependent (CTD), clients are screened to identify and reduce cardiovascular (CV) risk factors. In our study we have focused on the role of the CTD in reducing global CV risk. METHODS: 1,334 CTD patients aged 25-64 years (52.2% men, mean age 44±12 years, Fagerström Test for Cigarette Dependence 6±2) were included in a retrospective cross-sectional survey. Medical history, blood samples and physical examination were analysed. Blood pressure, weight and exhaled CO were measured at each visit (12-months-follow-up). Patients' CV risk was scored. CO-verified abstinence according to CV risk and prevalence of detected CV risk factors were examined. RESULTS: Among patients who had attended at least their first visit and a visit after one year, 37.9% (506/1,334) had stopped smoking. Among patients with a SCORE of <5%, the success rate was 44.3% (254/574) and 41.2% for patients at high CV risk (105/255, p=0.41). There was a trend towards a lower success rate among patients with CVD, but this difference was not significant. The smoking cessation rate among low and high CV risk patients at the baseline visit was identical (46.2%, resp. 47.3%, p=0.81). 3.1% (42/1,334) of patients were referred to a specialist for hypertension. 62.5% (223/357), without a prior history, were found to have dyslipidemia. CONCLUSIONS: High CV risk patients have the same chance to stop smoking as low risk patients.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a kardiovaskulární nemoci $x epidemiologie $x prevence a kontrola $7 D002318
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a logistické modely $7 D016015
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multivariační analýza $7 D015999
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a chování snižující riziko $7 D040242
- 650 _2
- $a odvykání kouření $x statistika a číselné údaje $7 D016540
- 650 _2
- $a poruchy vyvolané užíváním tabáku $x epidemiologie $x terapie $7 D014029
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Králíková, Eva, $u - $d 1956- $7 jn20000401512
- 700 1_
- $a Pánková, Alexandra $u - $7 xx0195009
- 700 1_
- $a Štěpánková, Lenka $u - $7 xx0159606
- 700 1_
- $a Blaha, Milan $u - $7 xx0209712
- 700 1_
- $a Sticha, Michal $u -
- 700 1_
- $a Bortlíček, Zbyněk $u - $7 xx0194424
- 700 1_
- $a Češka, Richard, $u - $d 1957- $7 nlk19990074195
- 773 0_
- $w MED00168352 $t Neuro endocrinology letters $x 0172-780X $g Roč. 33 Suppl 2(2012), s. 102-107
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23183520 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20190708143945 $b ABA008
- 999 __
- $a ok $b bmc $g 987781 $s 822481
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 33 Suppl 2 $d 102-107 $i 0172-780X $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
- GRA __
- $a NT12170 $p MZ0
- LZP __
- $a Pubmed-20130703